D-Wave Quantum vs. QuantumScape: Here Is the Better Innovative Technology Stock to Buy in 2026

D-Wave reported FY2025 revenue of $24.6 million, up 178.5% year over year, but posted a $355.1 million net loss and negative $75.8 million in free cash flow; its price-to-sales ratio was 396.3x. QuantumScape had no FY2025 sales, a $435.1 million net loss and negative $278.8 million in free cash flow, and management said a commercial product is not expected before at least 2029. The article favors D-Wave as the relatively more attractive investment, while emphasizing significant risks for both companies.

Analysis

The relative case favors QBTS only as the less distant commercialization story—not as an attractive valuation by default. Its revenue base offers a way to test whether optimization workloads convert into repeatable cloud and system demand, but growth from a small base does little to justify a 396x P/S on its own. The key evidence is customer expansion, repeat usage, and revenue quality; partner names such as CGI and BASF are not proof of material or recurring economics. Low reported leverage also does not remove dilution risk when cash flow is negative. The gate-model push adds potential addressable market but creates execution and integration risk alongside the existing annealing business.

QS is a longer-duration technical option: Volkswagen/PowerCo alignment may support development, but it does not establish cell qualification, manufacturing yield, or a binding volume program. A 2029 commercial horizon leaves substantial time for technical setbacks, competing battery chemistries, and further capital needs. The cited Q2 cash balance should not be treated as a guaranteed runway without updated burn, commitments, and financing assumptions.

Near term, both are exposed to speculative-growth de-rating; over 1–3 months, QBTS bookings, repeat customer activity, and cash burn matter more than headline revenue growth, while QS technical and partner milestones are the gating signals. Over 6–18 months, successful QBTS gate-model progress or QS independently verified manufacturing validation could change the relative ranking. The contrarian risk is that investors treat QBTS revenue as proof of scalable economics and QS's long timeline as proof of failure; neither follows from the available data.

Key Decisions for Investors

• Prefer QBTS over QS only on a relative, risk-budgeted basis; do not equate that preference with an outright buy at the cited sales multiple. Wait for evidence of repeat usage, backlog conversion, and improving cash economics.
• Avoid a long-QBTS/short-QS pair until QS valuation, borrow cost, and both companies’ updated liquidity and cash-burn data are verified. The two names have different-duration risks, so the hedge may not track the thesis.
• Treat QS as a milestone-driven watch, not a near-term commercialization trade. Reassess on independently verifiable cell performance, manufacturing yield, and Volkswagen/PowerCo qualification or volume commitments.
• Falsify the QBTS preference if bookings or recurring usage fail to convert into revenue, losses and cash burn worsen materially, or gate-model milestones slip; upgrade QS only if technical validation and production economics advance ahead of the stated timeline.